RARγ agonist treatment benefits have previously demonstrated the ability to translate from preclinical models to patient use with phase 3 clinical investigation of fibrodysplasia ossificans progressive (NCT03312634) and phase 2 investigation of multiple osteochondromas (NCT03442985) currently ongoing [37]. This evidence concerns the gene RARG and Osteochondroma.